首页 > 最新文献

Bone Reports最新文献

英文 中文
Development of fatty acid analogues with potent anabolic effects on bone in male mice 对雄性小鼠骨具有强合成代谢作用的脂肪酸类似物的研制
IF 2.6 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-07-30 DOI: 10.1016/j.bonr.2025.101862
Jian-ming Lin , Ivo Dimitrov , Karen E. Callon , Maureen Watson , Ian R. Reid , William A. Denny , Jillian Cornish
Natural fatty acids are inhibitory to osteoclastogenesis, but only mildly so, as reported earlier by our and other groups. To improve the potency, we have synthesized two categories of analogues based on the backbone of saturated palmitic acid by inserting an ether or a triazole group in the carbon chain. The most effective compound proved to be with a triazole moiety farthest away from the acid unit. Following this strategy, we now have developed even more potent molecules, methylated triazole and tetrazole analogues. Tetrazole analogue displays about 10-fold higher inhibitory activity over the natural counterpart as tested in the osteoclastogenesis assay using mouse bone marrow cell cultures. Importantly, this inhibition is not due to cytotoxicity as both the methylated triazole and tetrazole molecules slightly increase the viability of bone marrow cells. It was found that the inhibition of osteoclastogenesis by the tetrazole analogue in mouse bone marrow cultures is associated with the decreased expression of the key osteoclastogenic or osteoclastic marker genes: Dcstamp, Nfatc1, Tnfa, Trap and Ctsk. The best analogue-tetrazole was then tested in vivo in a mouse calvarial local injection model after being solubilized by (2-hydroxypropyl)-β-cyclodextrin (β-CD). The results show that the tetrazole at the daily dose of 40 μg/injection (along with 264 μg β-CD) significantly reduce TRAP surface, and significantly increased mineralizing surface/bone surface, mineral apposition rate and bone formation rate. This study provides a novel effective agent for inhibiting osteoclastogenesis and positively regulating bone homeostasis.
天然脂肪酸对破骨细胞的形成有抑制作用,但只有轻微的抑制作用,正如我们和其他研究小组先前所报道的那样。为了提高效力,我们在饱和棕榈酸的骨架上,通过在碳链上插入醚或三唑,合成了两类类似物。最有效的化合物被证明是离酸单元最远的三唑部分。根据这一策略,我们现在已经开发出更有效的分子,甲基化三唑和四唑类似物。在小鼠骨髓细胞培养的破骨细胞生成实验中,四氮唑类似物显示出比天然对应物高10倍的抑制活性。重要的是,这种抑制不是由于细胞毒性,因为甲基化的三唑和四唑分子都会略微增加骨髓细胞的活力。在小鼠骨髓培养中发现,四唑类似物对破骨细胞生成的抑制作用与关键破骨细胞或破骨细胞标记基因Dcstamp、Nfatc1、Tnfa、Trap和Ctsk的表达降低有关。然后用(2-羟丙基)-β-环糊精(β-CD)溶解后,在小鼠颅骨局部注射模型中进行体内实验。结果表明,日剂量为40 μg/次的四唑(与264 μg β-CD一起)显著降低了TRAP表面,显著提高了矿化面/骨表面、矿物附着率和骨形成率。本研究为抑制破骨细胞生成和积极调节骨稳态提供了一种新的有效药物。
{"title":"Development of fatty acid analogues with potent anabolic effects on bone in male mice","authors":"Jian-ming Lin ,&nbsp;Ivo Dimitrov ,&nbsp;Karen E. Callon ,&nbsp;Maureen Watson ,&nbsp;Ian R. Reid ,&nbsp;William A. Denny ,&nbsp;Jillian Cornish","doi":"10.1016/j.bonr.2025.101862","DOIUrl":"10.1016/j.bonr.2025.101862","url":null,"abstract":"<div><div>Natural fatty acids are inhibitory to osteoclastogenesis, but only mildly so, as reported earlier by our and other groups. To improve the potency, we have synthesized two categories of analogues based on the backbone of saturated palmitic acid by inserting an ether or a triazole group in the carbon chain. The most effective compound proved to be with a triazole moiety farthest away from the acid unit. Following this strategy, we now have developed even more potent molecules, methylated triazole and tetrazole analogues. Tetrazole analogue displays about 10-fold higher inhibitory activity over the natural counterpart as tested in the osteoclastogenesis assay using mouse bone marrow cell cultures. Importantly, this inhibition is not due to cytotoxicity as both the methylated triazole and tetrazole molecules slightly increase the viability of bone marrow cells. It was found that the inhibition of osteoclastogenesis by the tetrazole analogue in mouse bone marrow cultures is associated with the decreased expression of the key osteoclastogenic or osteoclastic marker genes: <em>Dcstamp</em>, <em>Nfatc1</em>, <em>Tnfa</em>, <em>Trap</em> and <em>Ctsk</em>. The best analogue-tetrazole was then tested <em>in vivo</em> in a mouse calvarial local injection model after being solubilized by (2-hydroxypropyl)-β-cyclodextrin (β-CD). The results show that the tetrazole at the daily dose of 40 μg/injection (along with 264 μg β-CD) significantly reduce TRAP surface, and significantly increased mineralizing surface/bone surface, mineral apposition rate and bone formation rate. This study provides a novel effective agent for inhibiting osteoclastogenesis and positively regulating bone homeostasis.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"26 ","pages":"Article 101862"},"PeriodicalIF":2.6,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144779432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Osteoblasts sense extracellular levels of phosphate to control the local expression of phosphatases for matrix mineralisation 成骨细胞通过感知细胞外的磷酸盐水平来控制磷酸酶在基质矿化中的局部表达
IF 2.6 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-07-30 DOI: 10.1016/j.bonr.2025.101863
Soher Nagi Jayash, Thomas Duff, Qaisar Tanveer, Worachet Promruk, Colin Farquharson
The provision of inorganic phosphate (Pi) for biomineralisation is under systemic and local control. Locally, osteoblast production of phosphatases such as tissue-nonspecific alkaline phosphatase (TNAP) and PHOSPHO1 is required for normal skeletal mineralisation and osteoblasts may sense extracellular Pi concentrations to control local phosphatase activity and thereby “fine-tune” Pi production and delivery for biomineralisation. This has been poorly explored and this study examined the ability of osteoblasts to sense and respond to extracellular Pi to control the local expression of TNAP and PHOSPHO1.
Extracellular Pi downregulated the expression of PHOSPHO1 and TNAP by human primary osteoblasts at both mRNA and protein levels. Increasing Pi concentrations also reduced the mRNA expression of the type III Na- Pi co-transporters, PiT-1 and PiT-2 and selectively enhanced ERK1/2 phosphorylation. Inhibition of PiT-1 and PiT-2 by Foscarnet or MEK1/2 by UO126 abolished the downregulation of PHOSPHO1 and ALPL expression by extracellular Pi. Moreover, extracellular Pi phosphorylated fibroblast growth factor receptor (FGFR) substrate 2α (FRS2α) and this activation was abolished by Foscarnet. Also, blocking FGFR signalling inhibited the phosphorylation of ERK1/2 and prevented the decrease in ALPL and PHOSPHO1 expression by extracellular Pi. Similar results were observed in cultured murine calvaria. Osteoblast matrix mineralisation by extracellular Pi was dependent upon type III Na- Pi co-transporters and FGFR signalling.
In conclusion, these results suggest an interplay between FGFR and Pi transporters is required for osteoblasts to sense and respond to extracellular Pi. This understanding advances our knowledge of the molecular control of physiological bone mineralisation by osteoblasts.
无机磷酸盐(Pi)的生物矿化是在系统和局部控制下提供的。局部,成骨细胞产生的磷酸酶,如组织非特异性碱性磷酸酶(TNAP)和PHOSPHO1,是正常骨骼矿化所必需的,成骨细胞可以感知细胞外Pi浓度来控制局部磷酸酶活性,从而“微调”Pi的产生和传递,以实现生物矿化。这方面的研究很少,本研究检测了成骨细胞感知和响应细胞外Pi的能力,以控制TNAP和PHOSPHO1的局部表达。胞外Pi在mRNA和蛋白水平上下调人原代成骨细胞PHOSPHO1和TNAP的表达。增加Pi浓度也降低了III型Na- Pi共转运体pit1和pit2的mRNA表达,并选择性地增强了ERK1/2的磷酸化。UO126对Foscarnet或MEK1/2对PiT-1和PiT-2的抑制消除了细胞外Pi对PHOSPHO1和ALPL表达的下调。此外,胞外Pi磷酸化成纤维细胞生长因子受体(FGFR)底物2α (FRS2α),这种激活被Foscarnet消除。此外,阻断FGFR信号传导可抑制ERK1/2的磷酸化,阻止细胞外Pi对ALPL和PHOSPHO1表达的降低。在培养的小鼠颅骨中也观察到类似的结果。细胞外Pi的成骨细胞基质矿化依赖于III型Na- Pi共转运蛋白和FGFR信号传导。总之,这些结果表明,FGFR和Pi转运蛋白之间的相互作用是成骨细胞感知和响应细胞外Pi的必要条件。这种理解促进了我们对成骨细胞生理骨矿化的分子控制的认识。
{"title":"Osteoblasts sense extracellular levels of phosphate to control the local expression of phosphatases for matrix mineralisation","authors":"Soher Nagi Jayash,&nbsp;Thomas Duff,&nbsp;Qaisar Tanveer,&nbsp;Worachet Promruk,&nbsp;Colin Farquharson","doi":"10.1016/j.bonr.2025.101863","DOIUrl":"10.1016/j.bonr.2025.101863","url":null,"abstract":"<div><div>The provision of inorganic phosphate (P<sub>i</sub>) for biomineralisation is under systemic and local control. Locally, osteoblast production of phosphatases such as tissue-nonspecific alkaline phosphatase (TNAP) and PHOSPHO1 is required for normal skeletal mineralisation and osteoblasts may sense extracellular P<sub>i</sub> concentrations to control local phosphatase activity and thereby “fine-tune” P<sub>i</sub> production and delivery for biomineralisation. This has been poorly explored and this study examined the ability of osteoblasts to sense and respond to extracellular P<sub>i</sub> to control the local expression of TNAP and PHOSPHO1.</div><div>Extracellular P<sub>i</sub> downregulated the expression of PHOSPHO1 and TNAP by human primary osteoblasts at both mRNA and protein levels. Increasing P<sub>i</sub> concentrations also reduced the mRNA expression of the type III Na- P<sub>i</sub> co-transporters, PiT-1 and PiT-2 and selectively enhanced ERK1/2 phosphorylation. Inhibition of PiT-1 and PiT-2 by Foscarnet or MEK1/2 by UO126 abolished the downregulation of <em>PHOSPHO1</em> and <em>ALPL</em> expression by extracellular Pi. Moreover, extracellular P<sub>i</sub> phosphorylated fibroblast growth factor receptor (FGFR) substrate 2α (FRS2α) and this activation was abolished by Foscarnet. Also, blocking FGFR signalling inhibited the phosphorylation of ERK1/2 and prevented the decrease in <em>ALPL</em> and <em>PHOSPHO1</em> expression by extracellular P<sub>i</sub>. Similar results were observed in cultured murine calvaria. Osteoblast matrix mineralisation by extracellular P<sub>i</sub> was dependent upon type III Na- P<sub>i</sub> co-transporters and FGFR signalling.</div><div>In conclusion, these results suggest an interplay between FGFR and P<sub>i</sub> transporters is required for osteoblasts to sense and respond to extracellular P<sub>i</sub>. This understanding advances our knowledge of the molecular control of physiological bone mineralisation by osteoblasts.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"26 ","pages":"Article 101863"},"PeriodicalIF":2.6,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144750368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experimental analysis of bone marrow adipose tissue and bone marrow adipocytes: An update from the bone marrow adiposity society (BMAS) 骨髓脂肪组织和骨髓脂肪细胞的实验分析:来自骨髓脂肪学会(BMAS)的最新进展
IF 2.6 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-07-28 DOI: 10.1016/j.bonr.2025.101861
Michaela Tencerova , Biagio Palmisano , Stéphanie Lucas , Camille Attané , Kaisa K. Ivaska , Léa Loisay , Yoshiko M. Ikushima , Drenka Trivanovic , Alessandro Corsi , Adriana Roque , Hongshuai Li , Friederike Behler-Janbeck , Jeroen Geurts , Mara Riminucci , Izabela Podgorski , William P. Cawthorn , Bram C.J. van der Eerden , André J. van Wijnen
Bone marrow adipose tissue (BMAT) is physiologically linked to bone and energy metabolism, endocrine regulation, hematopoiesis and cancer-related processes. A key challenge in the field is that methods for isolating BMAT or bone marrow adipocytes (BMAds) are variable because there are no widely adopted standardized protocols. To generate awareness of this challenge and to establish uniformity in experimental approaches requiring isolation, storage and characterization of BMAT and BMAds, the Biobanking Working Group of the international Bone Marrow Adiposity Society (BMAS) has previously recommended experimental standards. This paper provides an update on this effort and presents current state-of-the-art methods and technical considerations for isolation and characterization of BMAT and BMAds, including currently available high-throughput omics approaches. This review provides a reference point based on the consensus view of BMAS investigators to support studies on biomedical, biological, biochemical and biophysical questions associated with bone marrow adiposity.
骨髓脂肪组织(BMAT)在生理上与骨和能量代谢、内分泌调节、造血和癌症相关过程有关。该领域的一个关键挑战是分离BMAT或骨髓脂肪细胞(BMAds)的方法是可变的,因为没有广泛采用的标准化方案。为了提高对这一挑战的认识,并在需要分离、储存和表征BMAT和BMAds的实验方法上建立一致性,国际骨髓肥胖协会(BMAS)的生物银行工作组先前推荐了实验标准。本文提供了这项工作的最新进展,并介绍了目前最先进的分离和表征BMAT和BMAds的方法和技术考虑,包括目前可用的高通量组学方法。这篇综述提供了一个参考点,基于BMAS研究者的共识,以支持与骨髓肥胖相关的生物医学、生物学、生化和生物物理问题的研究。
{"title":"Experimental analysis of bone marrow adipose tissue and bone marrow adipocytes: An update from the bone marrow adiposity society (BMAS)","authors":"Michaela Tencerova ,&nbsp;Biagio Palmisano ,&nbsp;Stéphanie Lucas ,&nbsp;Camille Attané ,&nbsp;Kaisa K. Ivaska ,&nbsp;Léa Loisay ,&nbsp;Yoshiko M. Ikushima ,&nbsp;Drenka Trivanovic ,&nbsp;Alessandro Corsi ,&nbsp;Adriana Roque ,&nbsp;Hongshuai Li ,&nbsp;Friederike Behler-Janbeck ,&nbsp;Jeroen Geurts ,&nbsp;Mara Riminucci ,&nbsp;Izabela Podgorski ,&nbsp;William P. Cawthorn ,&nbsp;Bram C.J. van der Eerden ,&nbsp;André J. van Wijnen","doi":"10.1016/j.bonr.2025.101861","DOIUrl":"10.1016/j.bonr.2025.101861","url":null,"abstract":"<div><div>Bone marrow adipose tissue (BMAT) is physiologically linked to bone and energy metabolism, endocrine regulation, hematopoiesis and cancer-related processes. A key challenge in the field is that methods for isolating BMAT or bone marrow adipocytes (BMAds) are variable because there are no widely adopted standardized protocols. To generate awareness of this challenge and to establish uniformity in experimental approaches requiring isolation, storage and characterization of BMAT and BMAds, the Biobanking Working Group of the international Bone Marrow Adiposity Society (BMAS) has previously recommended experimental standards. This paper provides an update on this effort and presents current state-of-the-art methods and technical considerations for isolation and characterization of BMAT and BMAds, including currently available high-throughput omics approaches. This review provides a reference point based on the consensus view of BMAS investigators to support studies on biomedical, biological, biochemical and biophysical questions associated with bone marrow adiposity.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"26 ","pages":"Article 101861"},"PeriodicalIF":2.6,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144828523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of denosumab combination with proximal femoral nail antirotation surgery in elderly patients with intertrochanteric femoral fractures: A comparative study 地诺单抗联合股骨近端钉防旋转手术治疗老年股骨粗隆间骨折的疗效比较研究
IF 2.1 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-07-28 DOI: 10.1016/j.bonr.2025.101860
Xiaoqing Lu, Jun Zhu, Bai Zheng, Junsheng Wang

Objective

To evaluate the effect of denosumab combined with proximal femoral nail antirotation (PFNA) surgery in elderly patients with osteoporotic intertrochanteric femoral fractures (ITF Fx).

Design and Setting

This retrospective, comparative study included patients aged ≥65 years with osteoporotic ITF Fx who underwent PFNA fixation at Huai'an Second People's Hospital between July 2021 and July 2023.

Participants

Pain relief (visual analogue scale, VAS), hip function, bone mineral density (BMD), time to fracture healing, refracture rate, and adverse events were compared.

Interventions

This is a retrospective study, without the addition of any intervention measures.

Results

A total of 76 patients were included, with 38 patients in the denosumab + PFNA group and 38 in the PFNA group. The denosumab + PFNA group showed significantly greater improvements in pain relief (1.68 ± 0.93 vs 2.29 ± 0.97, p = 0.014) and BMD T-score (−1.49 ± 0.61 vs −1.98 ± 0.52, p = 0.006) at 12 months compared to the PFNA group. Fracture healing time was significantly shorter in the denosumab + PFNA group (12.37 ± 1.38 vs 13.63 ± 1.34 weeks, p < 0.001), and the refracture rate was significantly lower (2.63 % vs 21.05 %, p < 0.05) than that in the PFNA group. The post-treatment hip function was comparable between the denosumab + PFNA and PFNA groups. Only one case of hypocalcemia was reported in the denosumab + PFNA group (2.63 %).

Conclusion

Denosumab combined with PFNA surgery might have an advantage in pain relief, BMD T-score, and fracture healing, while reducing refracture risk in elderly patients with osteoporotic ITF Fx compared with PFNA surgery alone.
目的评价地诺单抗联合股骨近端钉防旋(PFNA)手术治疗老年骨质疏松性股骨粗隆间骨折(itffx)的疗效。设计和背景:这项回顾性比较研究纳入了2021年7月至2023年7月在淮安市第二人民医院接受PFNA固定的年龄≥65岁的骨质疏松性ITF Fx患者。比较参与者的西班牙缓解(视觉模拟量表,VAS)、髋关节功能、骨密度(BMD)、骨折愈合时间、再骨折率和不良事件。干预措施:这是一项回顾性研究,没有增加任何干预措施。结果共纳入76例患者,其中denosumab + PFNA组38例,PFNA组38例。与PFNA组相比,denosumab + PFNA组在12个月时疼痛缓解(1.68±0.93 vs 2.29±0.97,p = 0.014)和BMD t评分(- 1.49±0.61 vs - 1.98±0.52,p = 0.006)方面的改善显著大于PFNA组。denosumab + PFNA组骨折愈合时间明显缩短(12.37±1.38 vs 13.63±1.34周,p <;0.001),折射率明显低于(2.63% vs 21.05%, p <;0.05),高于PFNA组。治疗后髋关节功能在denosumab + PFNA和PFNA组之间具有可比性。denosumab + PFNA组仅报告1例低钙血症(2.63%)。结论与单纯PFNA手术相比,denosumab联合PFNA手术在老年骨质疏松性ITF Fx患者的疼痛缓解、BMD t评分和骨折愈合方面具有优势,同时可降低再骨折风险。
{"title":"Effect of denosumab combination with proximal femoral nail antirotation surgery in elderly patients with intertrochanteric femoral fractures: A comparative study","authors":"Xiaoqing Lu,&nbsp;Jun Zhu,&nbsp;Bai Zheng,&nbsp;Junsheng Wang","doi":"10.1016/j.bonr.2025.101860","DOIUrl":"10.1016/j.bonr.2025.101860","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the effect of denosumab combined with proximal femoral nail antirotation (PFNA) surgery in elderly patients with osteoporotic intertrochanteric femoral fractures (ITF Fx).</div></div><div><h3>Design and Setting</h3><div>This retrospective, comparative study included patients aged ≥65 years with osteoporotic ITF Fx who underwent PFNA fixation at Huai'an Second People's Hospital between July 2021 and July 2023.</div></div><div><h3>Participants</h3><div>Pain relief (visual analogue scale, VAS), hip function, bone mineral density (BMD), time to fracture healing, refracture rate, and adverse events were compared.</div></div><div><h3>Interventions</h3><div>This is a retrospective study, without the addition of any intervention measures.</div></div><div><h3>Results</h3><div>A total of 76 patients were included, with 38 patients in the denosumab + PFNA group and 38 in the PFNA group. The denosumab + PFNA group showed significantly greater improvements in pain relief (1.68 ± 0.93 vs 2.29 ± 0.97, <em>p</em> = 0.014) and BMD T-score (−1.49 ± 0.61 vs −1.98 ± 0.52, <em>p</em> = 0.006) at 12 months compared to the PFNA group. Fracture healing time was significantly shorter in the denosumab + PFNA group (12.37 ± 1.38 vs 13.63 ± 1.34 weeks, <em>p</em> &lt; 0.001), and the refracture rate was significantly lower (2.63 % vs 21.05 %, <em>p</em> &lt; 0.05) than that in the PFNA group. The post-treatment hip function was comparable between the denosumab + PFNA and PFNA groups. Only one case of hypocalcemia was reported in the denosumab + PFNA group (2.63 %).</div></div><div><h3>Conclusion</h3><div>Denosumab combined with PFNA surgery might have an advantage in pain relief, BMD T-score, and fracture healing, while reducing refracture risk in elderly patients with osteoporotic ITF Fx compared with PFNA surgery alone.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"26 ","pages":"Article 101860"},"PeriodicalIF":2.1,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144713413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The supercritical CO2 process does not affect the mechanical properties and the microarchitecture of trabecular bone at the microscopic scale: A microindentation and microcomputed tomography study 超临界CO2过程在微观尺度上不影响骨小梁的力学性能和微结构:微压痕和微计算机断层扫描研究
IF 2.1 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-07-25 DOI: 10.1016/j.bonr.2025.101859
Théo Krieger , Virginie Taillebot , Aurélien Maurel-Pantel , Claire Camy , Grégoire Edorh , Matthieu Ollivier , Martine Pithioux
Bone allografts are frequently used in many surgical procedures because of their osteoconductive and osteoinductive properties. After being extracted from the donor, the graft is treated with a process that cleans and sterilizes it before being implanted in the patient. While they guarantee the safety of the patient receiving the graft, preservation processes often affect bone properties.
This study aims to measure the effect of a supercritical CO2 process on the microarchitecture and the mechanical properties of trabecular bone at a microscopic scale using microindentation. 7 femoral heads were harvested from patients who had undergone a total hip arthroplasty. 42 cubic samples of 10 mm side from these femoral heads were randomly distributed in 3 groups: frozen at −20 °C, gamma irradiated and frozen at −20 °C, and treated with a supercritical CO2 process including gamma irradiation. All samples were imaged by microtomography and characterized by microindentation to correlate the bone microarchitecture with the mechanical properties at a microscopic scale.
Our results show that the supercritical CO2 process exerts no significant effect on the microarchitecture parameters, indentation elastic modulus, and indentation hardness.
The correlations between the microarchitecture and the mechanical properties revealed that gamma irradiation appears to induce a slight alteration in mechanical properties. However, the process combining a supercritical CO2 treatment and gamma irradiation does not induce any more alterations to the material than gamma irradiation itself. Thus, the supercritical CO2 process has no more impact than gamma irradiation on the mechanical properties of trabecular bone at the microscopic scale.
同种异体骨移植由于具有骨导电性和骨诱导性,在许多外科手术中经常使用。从供体中取出后,移植物在植入病人体内之前要经过清洁和消毒的处理。虽然它们保证了接受移植物的患者的安全,但保存过程通常会影响骨特性。本研究旨在利用微压痕在微观尺度上测量超临界CO2过程对小梁骨微结构和力学性能的影响。从接受全髋关节置换术的患者中取出7个股骨头。从这些股骨头中取出42个10 mm侧面的立方样品,随机分为3组:- 20°C冷冻、γ辐照和- 20°C冷冻,并进行包括γ辐照在内的超临界CO2处理。所有样品都通过显微断层成像和微压痕表征,以在微观尺度上将骨微结构与力学性能联系起来。结果表明,超临界CO2工艺对微结构参数、压痕弹性模量和压痕硬度没有显著影响。微观结构与力学性能之间的相关性表明,γ辐照似乎会引起力学性能的轻微变化。然而,将超临界CO2处理和伽马射线照射相结合的过程不会比伽马射线照射本身对材料产生更多的改变。因此,超临界CO2过程在微观尺度上对骨小梁力学性能的影响并不大于γ辐照。
{"title":"The supercritical CO2 process does not affect the mechanical properties and the microarchitecture of trabecular bone at the microscopic scale: A microindentation and microcomputed tomography study","authors":"Théo Krieger ,&nbsp;Virginie Taillebot ,&nbsp;Aurélien Maurel-Pantel ,&nbsp;Claire Camy ,&nbsp;Grégoire Edorh ,&nbsp;Matthieu Ollivier ,&nbsp;Martine Pithioux","doi":"10.1016/j.bonr.2025.101859","DOIUrl":"10.1016/j.bonr.2025.101859","url":null,"abstract":"<div><div>Bone allografts are frequently used in many surgical procedures because of their osteoconductive and osteoinductive properties. After being extracted from the donor, the graft is treated with a process that cleans and sterilizes it before being implanted in the patient. While they guarantee the safety of the patient receiving the graft, preservation processes often affect bone properties.</div><div>This study aims to measure the effect of a supercritical CO<sub>2</sub> process on the microarchitecture and the mechanical properties of trabecular bone at a microscopic scale using microindentation. 7 femoral heads were harvested from patients who had undergone a total hip arthroplasty. 42 cubic samples of 10 mm side from these femoral heads were randomly distributed in 3 groups: frozen at −20 °C, gamma irradiated and frozen at −20 °C, and treated with a supercritical CO<sub>2</sub> process including gamma irradiation. All samples were imaged by microtomography and characterized by microindentation to correlate the bone microarchitecture with the mechanical properties at a microscopic scale.</div><div>Our results show that the supercritical CO<sub>2</sub> process exerts no significant effect on the microarchitecture parameters, indentation elastic modulus, and indentation hardness.</div><div>The correlations between the microarchitecture and the mechanical properties revealed that gamma irradiation appears to induce a slight alteration in mechanical properties. However, the process combining a supercritical CO<sub>2</sub> treatment and gamma irradiation does not induce any more alterations to the material than gamma irradiation itself. Thus, the supercritical CO<sub>2</sub> process has no more impact than gamma irradiation on the mechanical properties of trabecular bone at the microscopic scale.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"26 ","pages":"Article 101859"},"PeriodicalIF":2.1,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144703986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abaloparatide effects on BMD in acetabular regions corresponding to DeLee and Charnley zones in women with postmenopausal osteoporosis 阿巴巴肽对绝经后骨质疏松症妇女髋臼区DeLee和Charnley区骨密度的影响
IF 2.6 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-07-19 DOI: 10.1016/j.bonr.2025.101858
Neil P. Sheth , Kelly Krohn , Jared Torkelson , Renaud Winzenrieth , Ludovic Humbert , Leny Pearman , Yamei Wang , John I. Boxberger , Mathias P. Bostrom

Background

Acetabular bone loss in patients with osteoporosis is associated with increased risk of acetabular fragility fractures, significant morbidity, and can increase risk of complications in patients undergoing total hip arthroplasty. The anabolic osteoporosis treatment abaloparatide increases total hip areal bone mineral density (BMD), but its effect on acetabular BMD is unknown.

Methods

Anatomical landmarks were identified in DXA scans from a random subgroup of postmenopausal women with osteoporosis (PMO) treated with abaloparatide 80 μg/d or placebo (n = 250/group) from the phase 3 ACTIVE trial to virtually place a hemispherical shell model of an acetabular cup and define regions of interest corresponding to DeLee and Charnley zones 1 (R1), 2 (R2), and 3 (R3). Changes in BMD from baseline at 6 and 18 months were calculated. Statistical significance was tested using a mixed model with repeated measures. Local mean changes in BMD were depicted by alignment of DXA scans via intensity-based registration onto a reference scan.

Results

Abaloparatide significantly increased acetabular areal BMD in all three DeLee and Charnley zones at 6 and 18 months versus placebo. Mean BMD increases with abaloparatide were 8.38 % (R1), 7.25 % (R2), and 9.73 % (R3) at 18 months. BMD increases were homogenously distributed throughout the regions. With placebo, localized losses in BMD were noted after 18 months.

Conclusions

Abaloparatide treatment rapidly and progressively increases BMD in acetabular zones in PMO.

Clinical trial number

NCT01343004.
背景:骨质疏松患者髋臼骨丢失与髋臼脆性骨折的风险增加、发病率显著相关,并可增加全髋关节置换术患者的并发症风险。合成代谢骨质疏松治疗阿巴巴拉肽可增加髋部总骨密度(BMD),但对髋臼骨密度的影响尚不清楚。方法对绝经后骨质疏松症(PMO)妇女随机亚组进行DXA扫描,该亚组接受阿巴帕肽80 μg/d或安慰剂(n = 250/组)治疗,从3期ACTIVE试验中放置一个半球形髋臼杯模型,并确定与DeLee和Charnley区1 (R1), 2 (R2)和3 (R3)相对应的兴趣区域。计算6个月和18个月时骨密度与基线的变化。采用重复测量的混合模型检验统计显著性。通过基于强度的配准与参考扫描的DXA扫描对齐来描述BMD的局部平均变化。结果与安慰剂相比,巴洛帕肽在6个月和18个月时显著增加了所有三个DeLee和Charnley区的髋臼面积骨密度。18个月时,阿巴巴拉肽的平均骨密度增加率分别为8.38% (R1)、7.25% (R2)和9.73% (R3)。骨密度增加在各区域均匀分布。使用安慰剂,18个月后发现局部骨密度下降。结论巴洛帕肽治疗可迅速、渐进地提高PMO患者髋臼区的骨密度。临床试验编号:bernct01343004。
{"title":"Abaloparatide effects on BMD in acetabular regions corresponding to DeLee and Charnley zones in women with postmenopausal osteoporosis","authors":"Neil P. Sheth ,&nbsp;Kelly Krohn ,&nbsp;Jared Torkelson ,&nbsp;Renaud Winzenrieth ,&nbsp;Ludovic Humbert ,&nbsp;Leny Pearman ,&nbsp;Yamei Wang ,&nbsp;John I. Boxberger ,&nbsp;Mathias P. Bostrom","doi":"10.1016/j.bonr.2025.101858","DOIUrl":"10.1016/j.bonr.2025.101858","url":null,"abstract":"<div><h3>Background</h3><div>Acetabular bone loss in patients with osteoporosis is associated with increased risk of acetabular fragility fractures, significant morbidity, and can increase risk of complications in patients undergoing total hip arthroplasty. The anabolic osteoporosis treatment abaloparatide increases total hip areal bone mineral density (BMD), but its effect on acetabular BMD is unknown.</div></div><div><h3>Methods</h3><div>Anatomical landmarks were identified in DXA scans from a random subgroup of postmenopausal women with osteoporosis (PMO) treated with abaloparatide 80 μg/d or placebo (n = 250/group) from the phase 3 ACTIVE trial to virtually place a hemispherical shell model of an acetabular cup and define regions of interest corresponding to DeLee and Charnley zones 1 (R1), 2 (R2), and 3 (R3). Changes in BMD from baseline at 6 and 18 months were calculated. Statistical significance was tested using a mixed model with repeated measures. Local mean changes in BMD were depicted by alignment of DXA scans via intensity-based registration onto a reference scan.</div></div><div><h3>Results</h3><div>Abaloparatide significantly increased acetabular areal BMD in all three DeLee and Charnley zones at 6 and 18 months versus placebo. Mean BMD increases with abaloparatide were 8.38 % (R1), 7.25 % (R2), and 9.73 % (R3) at 18 months. BMD increases were homogenously distributed throughout the regions. With placebo, localized losses in BMD were noted after 18 months.</div></div><div><h3>Conclusions</h3><div>Abaloparatide treatment rapidly and progressively increases BMD in acetabular zones in PMO.</div></div><div><h3>Clinical trial number</h3><div><span><span>NCT01343004</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"26 ","pages":"Article 101858"},"PeriodicalIF":2.6,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144723965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multigenerational genetic inheritance and clinical characteristics of the rare disease hypophosphatasia in 6 families: A case series 6家系罕见疾病磷酸酶减退症的多代遗传及临床特征
IF 2.1 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-07-15 DOI: 10.1016/j.bonr.2025.101857
Peter Kannu , Aliya A. Khan , Mira Francis , Jonathan D. Adachi
Family mapping is a useful tool for tracking the inheritance of rare inherited diseases, including hypophosphatasia (HPP), through generations. We show the inheritance of HPP in 6 affected families, describing genetic variants, biochemical hallmarks, and clinical manifestations among family members. Mapping families with HPP is warranted in clinical practice to better understand monitoring needs for potentially affected individuals over time, since manifestations of HPP can arise throughout a patient's lifespan.
家族图谱是一种有用的工具,用于追踪罕见遗传性疾病的遗传,包括低磷血症(HPP),通过代。我们展示了HPP在6个受影响家族中的遗传,描述了家族成员的遗传变异、生化特征和临床表现。在临床实践中,绘制HPP的家庭图是必要的,以便更好地了解随着时间的推移对潜在受影响个体的监测需求,因为HPP的表现可能在患者的整个生命周期中出现。
{"title":"Multigenerational genetic inheritance and clinical characteristics of the rare disease hypophosphatasia in 6 families: A case series","authors":"Peter Kannu ,&nbsp;Aliya A. Khan ,&nbsp;Mira Francis ,&nbsp;Jonathan D. Adachi","doi":"10.1016/j.bonr.2025.101857","DOIUrl":"10.1016/j.bonr.2025.101857","url":null,"abstract":"<div><div>Family mapping is a useful tool for tracking the inheritance of rare inherited diseases, including hypophosphatasia (HPP), through generations. We show the inheritance of HPP in 6 affected families, describing genetic variants, biochemical hallmarks, and clinical manifestations among family members. Mapping families with HPP is warranted in clinical practice to better understand monitoring needs for potentially affected individuals over time, since manifestations of HPP can arise throughout a patient's lifespan.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"26 ","pages":"Article 101857"},"PeriodicalIF":2.1,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144703987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
VEGF-A, -C, -D, VEGFR1, -2, -3, PDGF-BB and FGF-2 join forces to induce vascular and lymphatic angiogenesis during bone healing of hip implants VEGF-A、-C、-D、VEGFR1、-2、-3、PDGF-BB和FGF-2共同诱导髋关节植入物骨愈合过程中的血管和淋巴血管生成
IF 2.1 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-07-02 DOI: 10.1016/j.bonr.2025.101856
Jean Cassuto , Agnetha Folestad , Jan Göthlin , Henrik Malchau , Johan Kärrholm

Introduction

Angiogenic growth factors are a critical part of bone repair and regeneration in the aftermath of bone trauma. In the current study we monitored the spatiotemporal responses of angiogenic factors and receptors during the process of osseointegration of hip implants.

Materials and methods

Twenty-four patients having undergone primary total hip arthroplasty (THA) due to one-sided osteoarthritis (OA) were monitored during a period of 18 years (Y) by repeated measurements of plasma biomarkers as well as clinical and radiographic variables, the latter two showing all implants of the study to be well anchored throughout the follow-up. Eighty-one healthy donors divided into three gender- and age-matched subgroups and twenty OA patients awaiting THA, served as controls. Plasma was analyzed for vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF-D, vascular endothelial growth factor receptor 1 (VEGFR1) or sFlt-1, VEGFR2 (KDR/sFlk-1), VEGFR3 (sFlt-4), platelet derived growth factor–BB (PDGF-BB), fibroblast growth factor-2 (FGF-2) and placental growth factor (PIGF). Analysis of biomarkers was done by means of a high-sensitivity and wide dynamic range electrochemiluminescence technique allowing for detection of low levels and minor changes in biomarker levels. Spatiotemporal changes of biomarkers in THA patients during the follow-up were presented in the context of the four phases of endochondral bone repair.

Results

VEGF-A, VEGFR1, PDGF-BB and FGF-2 were significantly higher, whereas VEGF-C was significantly lower in presurgery OA patients versus healthy subjects but were all normalized shortly after implant surgery. VEGF-A, VEGF-C, VEGF-D, VEGFR2, VEGFR3, FGF-2 and PDGF-BB increased sharply 1–2 Y post-implant and reached a peak significantly above healthy control subjects at 5–7 Y after implant insertion before returning to control level 13-15Y post-surgery, except for VEGF-D that returned to control level at 7Y post-implant. VEGFR1 decreased to the level of healthy subjects at 6 W post-THA and remained there throughout the study. PIGF did not differ from healthy subjects at any point during the follow-up.

Conclusion

Increased levels of VEGF-A, VEGFR1, PDGF-BB and FGF-2 and reduced VEGF-C in presurgery OA relative healthy subjects support a cartilage protective or disease-inducing role in osteoarthritis. The concerted increase by all proangiogenic factors of the study, except VEGFR1 and PIGF, at 5 Y post-implant lend strong support to this being the phase of bone repair when blood and lymph vessels invade the avascular calcified hypertrophic cartilage and trigger its remodeling into bone in hip arthroplasty patients.
血管生成生长因子是骨创伤后骨修复和再生的关键部分。在本研究中,我们监测了髋关节骨整合过程中血管生成因子和受体的时空反应。材料和方法24例因单侧骨关节炎(OA)接受原发性全髋关节置换术(THA)的患者在18年(Y)期间通过反复测量血浆生物标志物以及临床和放射学变量进行监测,后两者显示研究中的所有植入物在整个随访期间锚定良好。81名健康供体分为三个性别和年龄匹配的亚组,20名等待THA的OA患者作为对照。分析血浆中血管内皮生长因子(VEGF)-A、VEGF- c、VEGF- d、血管内皮生长因子受体1 (VEGFR1)或sFlt-1、VEGFR2 (KDR/sFlk-1)、VEGFR3 (sFlt-4)、血小板衍生生长因子- bb (PDGF-BB)、成纤维细胞生长因子-2 (FGF-2)和胎盘生长因子(PIGF)的含量。生物标志物的分析是通过高灵敏度和宽动态范围的电化学发光技术完成的,允许检测低水平和微小变化的生物标志物水平。在软骨内骨修复的四个阶段的背景下,随访期间THA患者生物标志物的时空变化。结果术前OA患者的vegf - a、VEGFR1、PDGF-BB和FGF-2水平显著高于健康受试者,而VEGF-C水平显著低于健康受试者,但在植入手术后不久均恢复正常。VEGF-A、VEGF-C、VEGF-D、VEGFR2、VEGFR3、FGF-2和PDGF-BB在植入后1-2 Y急剧升高,在植入后5-7 Y达到峰值,术后13-15Y恢复到控制水平,但VEGF-D在植入后7Y恢复到控制水平。VEGFR1在tha后6周降至健康受试者的水平,并在整个研究过程中保持该水平。在随访期间,PIGF与健康受试者没有任何差异。结论术前OA相对健康患者VEGF-A、VEGFR1、PDGF-BB和FGF-2水平升高,VEGF-C水平降低,支持骨性关节炎软骨保护或疾病诱导作用。除VEGFR1和PIGF外,本研究中所有促血管生成因子在髋关节置换术后5 Y的一致增加,有力地支持了这是骨修复的阶段,此时血液和淋巴管侵入无血管钙化的肥厚软骨并触发其重塑成骨。
{"title":"VEGF-A, -C, -D, VEGFR1, -2, -3, PDGF-BB and FGF-2 join forces to induce vascular and lymphatic angiogenesis during bone healing of hip implants","authors":"Jean Cassuto ,&nbsp;Agnetha Folestad ,&nbsp;Jan Göthlin ,&nbsp;Henrik Malchau ,&nbsp;Johan Kärrholm","doi":"10.1016/j.bonr.2025.101856","DOIUrl":"10.1016/j.bonr.2025.101856","url":null,"abstract":"<div><h3>Introduction</h3><div>Angiogenic growth factors are a critical part of bone repair and regeneration in the aftermath of bone trauma. In the current study we monitored the spatiotemporal responses of angiogenic factors and receptors during the process of osseointegration of hip implants.</div></div><div><h3>Materials and methods</h3><div>Twenty-four patients having undergone primary total hip arthroplasty (THA) due to one-sided osteoarthritis (OA) were monitored during a period of 18 years (Y) by repeated measurements of plasma biomarkers as well as clinical and radiographic variables, the latter two showing all implants of the study to be well anchored throughout the follow-up. Eighty-one healthy donors divided into three gender- and age-matched subgroups and twenty OA patients awaiting THA, served as controls. Plasma was analyzed for vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF-D, vascular endothelial growth factor receptor 1 (VEGFR1) or sFlt-1, VEGFR2 (KDR/sFlk-1), VEGFR3 (sFlt-4), platelet derived growth factor–BB (PDGF-BB), fibroblast growth factor-2 (FGF-2) and placental growth factor (PIGF). Analysis of biomarkers was done by means of a high-sensitivity and wide dynamic range electrochemiluminescence technique allowing for detection of low levels and minor changes in biomarker levels. Spatiotemporal changes of biomarkers in THA patients during the follow-up were presented in the context of the four phases of endochondral bone repair.</div></div><div><h3>Results</h3><div>VEGF-A, VEGFR1, PDGF-BB and FGF-2 were significantly higher, whereas VEGF-C was significantly lower in presurgery OA patients versus healthy subjects but were all normalized shortly after implant surgery. VEGF-A, VEGF-C, VEGF-D, VEGFR2, VEGFR3, FGF-2 and PDGF-BB increased sharply 1–2 Y post-implant and reached a peak significantly above healthy control subjects at 5–7 Y after implant insertion before returning to control level 13-15Y post-surgery, except for VEGF-D that returned to control level at 7Y post-implant. VEGFR1 decreased to the level of healthy subjects at 6 W post-THA and remained there throughout the study. PIGF did not differ from healthy subjects at any point during the follow-up.</div></div><div><h3>Conclusion</h3><div>Increased levels of VEGF-A, VEGFR1, PDGF-BB and FGF-2 and reduced VEGF-C in presurgery OA relative healthy subjects support a cartilage protective or disease-inducing role in osteoarthritis. The concerted increase by all proangiogenic factors of the study, except VEGFR1 and PIGF, at 5 Y post-implant lend strong support to this being the phase of bone repair when blood and lymph vessels invade the avascular calcified hypertrophic cartilage and trigger its remodeling into bone in hip arthroplasty patients.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"26 ","pages":"Article 101856"},"PeriodicalIF":2.1,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fluorescent collagen hybridizing peptide for quantifying collagen denaturation in cortical bone 荧光胶原杂交肽定量测定骨皮质胶原变性
IF 2.1 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-06-26 DOI: 10.1016/j.bonr.2025.101855
William Woolley , Naomi Chin , S. Michael Yu , Claire Acevedo
Bone fracture risk is clinically assessed with bone mineral density (BMD); however, individuals with normal BMD also experience fractures, highlighting the need for complementary fracture risk assessment tools. While BMD remains the clinical gold standard, it fails to capture bone quality factors that contribute to fragility. Among these, collagen quality is essential for bone toughness, as it allows collagen to dissipate energy via stretching and uncoiling. When collagen is denatured, it loses its ability to deform, increasing fracture risk. This process is particularly relevant in aging, osteoporosis, and metabolic conditions such as diabetes, yet no clinical methods exist to quantify or localize denatured collagen in mineralized bone. This study introduces Collagen Hybridizing Peptide (CHP) as a tool to quantify denatured collagen in cortical bone. Here, we show that CHP fluorescence correlates strongly with collagen denaturation measured by established trypsin-hydroxyproline assay (r2 = 0.99) when applied to mineralized tissue subjected to heat treatment or mechanical loading. Confocal microscopy revealed a 55 % increase in collagen denaturation when tissue strain exceeded the yield point (p < 0.05). Our findings demonstrate that fluorescent CHP localizes high-strain regions to collagen denaturation on bone fracture surfaces, indicating that collagen damage occurs during post-yield failure. This non-destructive technique offers a powerful tool for assessing collagen quality, with potential applications in osteoporosis, diabetic bone fragility, and aging research. By advancing our ability to evaluate bone quality in cortical bone, R-CHP provides new method to study how denatures collagen affects bone resistance to fracture.
临床用骨密度(BMD)评估骨折风险;然而,骨密度正常的个体也会发生骨折,因此需要补充骨折风险评估工具。虽然骨密度仍然是临床的黄金标准,但它未能捕捉到导致脆弱的骨质量因素。其中,胶原蛋白的质量对骨骼韧性至关重要,因为它允许胶原蛋白通过拉伸和展开来消散能量。当胶原蛋白变性时,它失去了变形的能力,增加了骨折的风险。这一过程与衰老、骨质疏松和代谢疾病(如糖尿病)特别相关,但目前还没有临床方法来量化或定位矿化骨中的变性胶原。本研究引入胶原杂交肽(Collagen Hybridizing Peptide, CHP)作为量化皮质骨变性胶原的工具。在这里,我们发现CHP荧光与胶原变性密切相关,通过建立胰蛋白酶-羟脯氨酸测定法(r2 = 0.99),当应用于热处理或机械负荷的矿化组织时。共聚焦显微镜显示当组织应变超过屈服点时,胶原变性增加55% (p <;0.05)。我们的研究结果表明,荧光CHP将骨折表面的高应变区域定位为胶原变性,表明胶原损伤发生在屈服后失效期间。这种非破坏性的技术为评估胶原质提供了强有力的工具,在骨质疏松症、糖尿病骨脆性和衰老研究中具有潜在的应用前景。通过提高我们评估皮质骨骨质量的能力,R-CHP为研究变性胶原如何影响骨抗骨折性提供了新的方法。
{"title":"Fluorescent collagen hybridizing peptide for quantifying collagen denaturation in cortical bone","authors":"William Woolley ,&nbsp;Naomi Chin ,&nbsp;S. Michael Yu ,&nbsp;Claire Acevedo","doi":"10.1016/j.bonr.2025.101855","DOIUrl":"10.1016/j.bonr.2025.101855","url":null,"abstract":"<div><div>Bone fracture risk is clinically assessed with bone mineral density (BMD); however, individuals with normal BMD also experience fractures, highlighting the need for complementary fracture risk assessment tools. While BMD remains the clinical gold standard, it fails to capture bone quality factors that contribute to fragility. Among these, collagen quality is essential for bone toughness, as it allows collagen to dissipate energy via stretching and uncoiling. When collagen is denatured, it loses its ability to deform, increasing fracture risk. This process is particularly relevant in aging, osteoporosis, and metabolic conditions such as diabetes, yet no clinical methods exist to quantify or localize denatured collagen in mineralized bone. This study introduces Collagen Hybridizing Peptide (CHP) as a tool to quantify denatured collagen in cortical bone. Here, we show that CHP fluorescence correlates strongly with collagen denaturation measured by established trypsin-hydroxyproline assay (r<sup>2</sup> = 0.99) when applied to mineralized tissue subjected to heat treatment or mechanical loading. Confocal microscopy revealed a 55 % increase in collagen denaturation when tissue strain exceeded the yield point (<em>p</em> <em>&lt;</em> 0.05). Our findings demonstrate that fluorescent CHP localizes high-strain regions to collagen denaturation on bone fracture surfaces, indicating that collagen damage occurs during post-yield failure. This non-destructive technique offers a powerful tool for assessing collagen quality, with potential applications in osteoporosis, diabetic bone fragility, and aging research. By advancing our ability to evaluate bone quality in cortical bone, R-CHP provides new method to study how denatures collagen affects bone resistance to fracture.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"26 ","pages":"Article 101855"},"PeriodicalIF":2.1,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144501282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
p75NTR regulates postnatal skeletal development via NGF-responsive JNK signaling p75NTR通过ngf响应的JNK信号调控出生后骨骼发育
IF 2.1 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-06-13 DOI: 10.1016/j.bonr.2025.101854
Chiho Kadota-Watanabe , Jinsook Suh , Zhenqing Liu , Eric Yin , Kate Lindsey , Isabelle Lao-Ngo , Byron Zhao , Jonathan H. Wu , In Won Chang , Reuben H. Kim , Ophir D. Klein , Christine Hong
p75NTR has emerged as a key regulator of skeletal development and bone homeostasis. To define its role, we characterized skeletal phenotypes in global and mesenchyme-specific p75NTR knockout mouse models. Global deletion of p75NTR resulted in postnatal growth retardation, decreased trabecular and cortical bone mass, and impaired growth plate architecture—hallmarks of an osteoporotic phenotype that persisted into adulthood. Conditional deletion of p75NTR in mesenchymal progenitor cells using Prx1-Cre recapitulated these skeletal deficits, confirming a cell-autonomous role in bone development. In vitro, bone marrow stromal cells (BMSCs) derived from p75NTR-deficient mouse exhibited diminished osteogenic differentiation capacity, reduced mineralization, and downregulation of key osteogenic genes. Transcriptomic profiling revealed significant suppression of the NGF-MAPK/AP-1 signaling axis in p75NTR-deficient BMSCs. Functional studies demonstrated that loss of p75NTR reduced JNK pathway activation and downstream epigenetic regulators, including Kdm4b and its target gene Dlx5. Overexpression of Kdm4b rescued mineralization defects and restored osteogenic gene expression in p75NTR-deficient BMSCs, establishing a mechanistic link between p75NTR signaling and osteoblast differentiation. These findings define the NGF–p75NTR–JNK–KDM4B–Dlx5 axis as a central regulatory pathway in postnatal bone growth and osteogenesis. Given the critical role of p75NTR in skeletal development and bone homeostasis, targeted modulation of this signaling cascade may represent a promising therapeutic approach for treating osteoporosis and other bone disorders.
p75NTR已成为骨骼发育和骨骼稳态的关键调节因子。为了确定其作用,我们在p75NTR基因敲除小鼠模型中对骨骼表型进行了表征。p75NTR的整体缺失导致出生后生长迟缓,小梁和皮质骨量减少,生长板结构受损-骨质疏松症表型的标志持续到成年期。使用Prx1-Cre在间充质祖细胞中条件删除p75NTR再现了这些骨骼缺陷,证实了细胞在骨骼发育中的自主作用。在体外,来自p75ntr缺陷小鼠的骨髓基质细胞(BMSCs)表现出成骨分化能力减弱、矿化减少和关键成骨基因下调的现象。转录组学分析显示,在p75ntr缺失的骨髓间充质干细胞中,NGF-MAPK/AP-1信号轴受到显著抑制。功能研究表明,p75NTR的缺失降低了JNK通路的激活和下游表观遗传调控因子,包括Kdm4b及其靶基因Dlx5。在p75NTR缺失的骨髓间充质干细胞中,过表达Kdm4b可修复矿化缺陷并恢复成骨基因表达,从而在p75NTR信号传导与成骨细胞分化之间建立起机制联系。这些发现确定了NGF-p75NTR-JNK-KDM4B-Dlx5轴是出生后骨生长和成骨的中心调控途径。鉴于p75NTR在骨骼发育和骨稳态中的关键作用,靶向调节这一信号级联可能是治疗骨质疏松症和其他骨骼疾病的一种有希望的治疗方法。
{"title":"p75NTR regulates postnatal skeletal development via NGF-responsive JNK signaling","authors":"Chiho Kadota-Watanabe ,&nbsp;Jinsook Suh ,&nbsp;Zhenqing Liu ,&nbsp;Eric Yin ,&nbsp;Kate Lindsey ,&nbsp;Isabelle Lao-Ngo ,&nbsp;Byron Zhao ,&nbsp;Jonathan H. Wu ,&nbsp;In Won Chang ,&nbsp;Reuben H. Kim ,&nbsp;Ophir D. Klein ,&nbsp;Christine Hong","doi":"10.1016/j.bonr.2025.101854","DOIUrl":"10.1016/j.bonr.2025.101854","url":null,"abstract":"<div><div>p75<sup>NTR</sup> has emerged as a key regulator of skeletal development and bone homeostasis. To define its role, we characterized skeletal phenotypes in global and mesenchyme-specific <em>p75</em><sup><em>NTR</em></sup> knockout mouse models. Global deletion of <em>p75</em><sup><em>NTR</em></sup> resulted in postnatal growth retardation, decreased trabecular and cortical bone mass, and impaired growth plate architecture—hallmarks of an osteoporotic phenotype that persisted into adulthood. Conditional deletion of <em>p75</em><sup><em>NTR</em></sup> in mesenchymal progenitor cells using Prx1-Cre recapitulated these skeletal deficits, confirming a cell-autonomous role in bone development. In vitro, bone marrow stromal cells (BMSCs) derived from <em>p75</em><sup><em>NTR</em></sup>-deficient mouse exhibited diminished osteogenic differentiation capacity, reduced mineralization, and downregulation of key osteogenic genes. Transcriptomic profiling revealed significant suppression of the NGF-MAPK/AP-1 signaling axis in <em>p75</em><sup><em>NTR</em></sup>-deficient BMSCs. Functional studies demonstrated that loss of <em>p75</em><sup><em>NTR</em></sup> reduced JNK pathway activation and downstream epigenetic regulators, including <em>Kdm4b</em> and its target gene <em>Dlx5</em>. Overexpression of <em>Kdm4b</em> rescued mineralization defects and restored osteogenic gene expression in <em>p75</em><sup><em>NTR</em></sup>-deficient BMSCs, establishing a mechanistic link between p75<sup>NTR</sup> signaling and osteoblast differentiation. These findings define the NGF–p75<sup>NTR</sup>–JNK–KDM4B<em>–Dlx5</em> axis as a central regulatory pathway in postnatal bone growth and osteogenesis. Given the critical role of p75<sup>NTR</sup> in skeletal development and bone homeostasis, targeted modulation of this signaling cascade may represent a promising therapeutic approach for treating osteoporosis and other bone disorders.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"26 ","pages":"Article 101854"},"PeriodicalIF":2.1,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144322046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Bone Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1